Table 4 Risk factors for imperfect adherence (< 90%) in patients with information on actual dose administered
Adherence by actual dose administered | Univariable analyses | |||
|---|---|---|---|---|
≥ 90% (n = 2824) | < 90% (n = 86) | Unadjusted OR (95% CI) | p-value | |
Primaquine daily dose, every 0.25 mg/kg increase | 2824 (97.0%) | 86 (3.0%) | 1.1 (0.9–1.4) | 0.288 |
Primaquine regimen duration | ||||
14 days | 1604 (97.3%) | 45 (2.7%) | Ref. | . |
<14 days | 1220 (96.8%) | 41 (3.2%) | 1.2 (0.7–2.2) | 0.551 |
Start day of primaquine | ||||
Day 2/3 | 80 (97. 6%) | 2 (2.4%) | Ref. | . |
Day 0/1 | 2744 (97.0%) | 84 (3.0%) | 1.2 (0.8–1.8) | 0.323 |
Vomiting | ||||
No | 1314 (96.6%) | 46 (3.4%) | Ref. | . |
Yes | 518 (97.0%) | 16 (3.0%) | 0.9 (0.4–2.1) | 0.775 |
Sex | ||||
Male | 1815 (96.7%) | 63 (3.3%) | Ref | . |
Female | 1009 (97.8%) | 23 (2.2%) | 0.7 (0.4–1.0) | 0.068 |
Age (years) | 2824 (97.0%) | 86 (3.0%) | 1.0 (0.98–1.01) | 0.821 |
Age category (years) | ||||
≥ 15 | 1726 (96.8%) | 57 (3.2%) | Ref. | . |
5- < 15 | 930 (97.6%) | 23 (2.4%) | 0.8 (0.5–1.1) | 0.131 |
< 5 | 168 (96.6%) | 6 (3.4%) | 1.1 (0.4–2.9) | 0.878 |
Parasitaemia, parasites per μL every tenfold increase | 2768 (97.0%) | 85 (3.0%) | 1.0 (0.7–1.3) | 0.887 |
Fever at baseline, temperature > 37.5°C | ||||
No | 1609 (97.28%) | 45 (2.72%) | Ref. | . |
Yes | 1032 (96.45%) | 38 (3.55%) | 1.3 (0.8–2.1) | 0.246 |